News

Grenova Announces Katherine Marrs as New CEO to Drive Innovation and Growth

Grenova, an industry leader in sustainable laboratory solutions, has appointed Katherine Marrs as its new Chief Executive Officer (CEO). Marrs succeeds Lane Major, who has served as CEO since 2023 and will continue to support Grenova as a member of the Board of Directors.

Marrs has been instrumental in driving Grenova’s growth strategy as the company’s Chief Commercial Officer for the past 16 months. Her leadership has been pivotal in expanding Grenova’s presence in the European market and enhancing its commitment to sustainability within the Life Sciences industry.

“We are at an exciting juncture, and I am honored to lead Grenova as we drive forward,” said Marrs. “I look forward to building on our team’s accomplishments, enhancing our innovative product portfolio, advancing our automation and integration capabilities, and furthering our commitment to helping laboratories reduce their environmental footprint.”

Lane Major expressed his confidence in Marrs’ ability to lead Grenova into its next chapter. “Katherine has demonstrated remarkable vision and leadership during her time as Chief Commercial Officer. Her deep understanding of our business and commitment to innovation make her the perfect choice to lead Grenova.”

Ted Lundberg, Chairman of the Board of Directors for Grenova and Co-Founder of Peloton Equity, Grenova’s majority owner, said, “Katherine has shown remarkable skill in guiding Grenova’s commercial strategy and building a solid foundation for the company’s future. Her dedication, expertise, and strategic focus have proven invaluable, and we look forward to her continued success as CEO.”

As Grenova continues expanding its solutions, Marrs will leverage her expertise to enhance the company’s position in the market, foster partnerships that align with Grenova’s mission, and drive initiatives that further its dedication to environmental and economic responsibility.

 

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and